Selective removal of circulating immune complexes from patient plasma.

Autor: Kunkel S; R&D Center of Bioengineering GmbH, Rostock/Teterow, Germany. kunkel@cob.bioeng.de, Holtz M, Grossjohann B, Schuett W, Klinkmann H, Kong D, Yamada R, Kimura H, Matic GB, Ramlow W, Boeden HF
Jazyk: angličtina
Zdroj: Artificial organs [Artif Organs] 2002 Feb; Vol. 26 (2), pp. 124-32.
DOI: 10.1046/j.1525-1594.2002.06875.x
Abstrakt: The principle of a patient-specific immunoadsorber (PsIA) is demonstrated. Studies with model systems (HSA/anti-HSA) on immobilization, stability, and leakage form the basis for the presented fast-performance liquid chromatography (FPLC) and batch experiments, which were conducted using two different protein A adsorbers and autologous and heterologous PsIA systems. Experiments to determine the binding capacity of protein A adsorbers and PsIAs are described. In all experiments, the adsorption of plasma IgG, total protein, and C1q and C3d circulating immune complexes were measured. Plasma of patients with autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus) was investigated. Analysis was performed in both the initial plasma and the flow-through or supernatant. Results of the investigations using FPLC and batch experiments were compared. Autologous PsIA systems are suitable for the selective removal of elevated levels of circulating immune complexes in the plasma.
Databáze: MEDLINE